'Doctors must report pancreatic disease in diabetics'

Health Ministry announcement follows a warning by the US Food and Drug Administration and its European counterpart.

April 24, 2013 05:40
Doctors (illustrative)

Doctors perform surgery (generic) R 370. (photo credit: REUTERS/Swoan Parker)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For a symbolic $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The Health Ministry’s pharmaceutical division has asked doctors to be vigilant for cases of pancreatic infections and pancreatic cancer in diabetics taking incretins, drugs commercialized as Januet, Januvia, Byetta, Victoza, Galvus, Eucreas and Onglyza, among others.

Incretins are gastrointestinal hormones that increase the amount of insulin released from the beta cells of the islets of Langerhans in the pancreas.

Be the first to know - Join our Facebook page.

The announcement on Monday followed a warning by the US Food and Drug Administration and its European counterpart, EMA, which are following up a “possible connection” between taking the drugs and developing pancreatic infections or cancer in the organ.

The ministry and the National Diabetes Council have been asked to raise physicians’ awareness of possible side effects from this drug family. The ministry said the number of reports of side effects here seem to be lower than expected.

Doctors who noted such side effects were asked to report them via an electronic report to the ministry at http://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=Adv ersEffectMedic@moh.health.gov.il

Related Content

August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice